Please note that this program will include a

discussion of off-label uses of therapies in

some jurisdictions
Introduction
Evolution of Antipsychotics and MoA
Evolution of Antipsychotics and MoA
Evolution of Antipsychotics and MoA
Evolution of Antipsychotics and MoA
D2 Receptor Partial Agonism: Optimal Level of
Intrinsic Activity
D2 Receptor Partial Agonism: Optimal Level of
Intrinsic Activity
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Binding Affinities of the DRPAs in Vitro
Pharmacological Mechanisms of
Antipsychotics In MDD
Pharmacological Mechanisms of
Antipsychotics in MDD
Pharmacological Mechanisms of
Antipsychotics in MDD
Pharmacological Mechanisms of
Antipsychotics in MDD
Patient Case: Sonia
A Woman With MDD
Patient Case: Sonia
A Woman With MDD
Effect of MDD on Work and Family
Sonia
Effect of MDD on Work and Family
Sonia
Insufficient Pharmacological Response in
MDD
Possible Approaches
Insufficient Pharmacological Response in
MDD
Possible Approaches
Insufficient Pharmacological Response in
MDD
Possible Approaches
Insufficient Pharmacological Response in
MDD
Possible Approaches
DRPAs and MDD: Number Needed to Treat
for Therapeutic Response
DRPA Efficacy in Anxious Depression
Brexpiprazole
DRPAs in Preventing Relapse in MDD
DRPAs in Preventing Relapse in MDD
DRPAs in Preventing Relapse in MDD
DRPAs and Activation in MDD
Number Needed to Harm
DRPAs and Sedation in MDD
Number Needed to Harm
Why Might a DRPA Be a Suitable Choice for
Sonia?
Patient Case: Jeanne
A Young Woman With Schizophrenia
Patient Case: Jeanne
A Young Woman With Schizophrenia
Variables to Consider in Treatment Choice
Possible Adverse Effects
Acute Treatment of Agitation in Patients With
Schizophrenia
Olanzapine vs Aripiprazole
Improvement in PANSS Total Score Over 4
Weeks
Aripiprazole vs Risperidone
DRPAs in Preventing Relapse in
Schizophrenia
DRPAs in Preventing Relapse in
Schizophrenia
DRPAs and Schizophrenia: Number Needed
to Treat
for Therapeutic Response
Increased Functionality With DRPAs vs Other Antipsychotics
Improvement in Personal and Social Performance Scale Score
Brexpiprazole
DRPAs and Activation in Schizophrenia
Number Needed to Harm
DRPAs and Sedation in Schizophrenia
Number Needed to Harm
Long-Term Effect of DRPAs on Weight
Closing Remarks
Basic Intro Slide